Resverlogix (FRA:RFS) 3-Year RORE % : -17.27% (As of Mar. 2026)


FRA:RFS Resverlogix Corp FRA:RFS
39 GF Score
Price €0.05
! 4 Warning Signs
View Full Analysis

What is Resverlogix 3-Year RORE %?

Resverlogix FRA:RFS +6.06% 39 3-Year RORE % is -17.27 as of Mar. 2026. GuruFocus rates FRA:RFS with a GF Score™ of 39/100. The stock has 4 warning signs investors should review. Among 1,294 Biotechnology companies, Resverlogix ranks worse than 53.71% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Resverlogix's 3-Year RORE % for the quarter that ended in Mar. 2026 was -17.27%.

The industry rank for Resverlogix's 3-Year RORE % or its related term are showing as below:

FRA:RFS's 3-Year RORE % is ranked worse than
53.71% of 1294 companies
in the Biotechnology industry
Industry Median: -11.54 vs FRA:RFS: -17.27

Resverlogix  (FRA:RFS) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Resverlogix 3-Year RORE % Related Terms


Resverlogix 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Resverlogix's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix 3-Year RORE % Chart

Resverlogix Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -20.00 23.81 -24.17

Resverlogix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.95 13.22 -9.91 -24.17 -17.27

FRA:RFS vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, Resverlogix's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Resverlogix's 3-Year RORE % falls into.


FRA:RFS
39GF Score
Resverlogix Corp FRA:RFS
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Resverlogix 3-Year RORE % Calculation

Resverlogix's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.018--0.037 )/( -0.11-0 )
=0.019/-0.11
=-17.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -17.27 mean?
Resverlogix (FRA:RFS) has a 3-Year RORE % of -17.27 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Resverlogix and its competitors. According to the industry distribution chart, Resverlogix ranks #695 out of 1294 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Resverlogix's 3-Year RORE % too high?
Resverlogix's current 3-Year RORE % is -17.27. Based on the distribution chart, Resverlogix ranks #695 out of 1294 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Resverlogix has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Resverlogix's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Resverlogix ranks #695 out of 1294 companies for 3-Year RORE %. This places Resverlogix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Resverlogix and its competitors. Resverlogix's current 3-Year RORE % is -17.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resverlogix stock overvalued right now?
Resverlogix (FRA:RFS) has a current 3-Year RORE % of -17.27. The current 3-Year RORE % is -17.27. Resverlogix's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Resverlogix (FRA:RFS), the current 3-Year RORE % is -17.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resverlogix Business Description

Other Exchanges RVXCF:USARVX:Canada
Address 4820 Richard Road SW, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
39GF Score

Get the complete analysis for FRA:RFS

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price